PATENT CLAIM ANALYSIS

Application Number: 15943436
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "009100"]

Abstract:
The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.

Claim (Index 4):
The polypeptide of  claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 33.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 91.0
- Lexical Diversity: 1.25926
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13466672', '12784117', '13336651', '10734661', '12394756']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8062266766361956
- 35 USC 102 Novelty (BERT): 0.5351291705984462
- Combined Prediction Score: 0.7791169260324207
- Mean Citation Score: 328.42445800000013
- Max Citation Score: 338.0359
- Similarity Product: 216.85071360982656

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test